Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Multiple sclerosis (MS) is a complex disease with a presumed autoimmune aetiology and few current effective treatments. Disease modifying therapies focus on the altering the natural course of relapsing and remitting MS, targeting the inflammatory response. Other targets involve tacking the cause of the disease - demyelination of axons through remyelination therapies. Due to several recent breakthroughs in the understanding of the pathophysiology of MS new targets for remyelination and immunomodulation are rapidly emerging. This book provides a comprehensive overview of drug discovery and…mehr
Multiple sclerosis (MS) is a complex disease with a presumed autoimmune aetiology and few current effective treatments. Disease modifying therapies focus on the altering the natural course of relapsing and remitting MS, targeting the inflammatory response. Other targets involve tacking the cause of the disease - demyelination of axons through remyelination therapies. Due to several recent breakthroughs in the understanding of the pathophysiology of MS new targets for remyelination and immunomodulation are rapidly emerging. This book provides a comprehensive overview of drug discovery and development for the molecular basis of the disease, from new targets to drugs currently in clinical development, cellular and animal disease models to biomarkers for diagnosis and assessment in clinical trials. Emerging Drugs and Targets for Multiple Sclerosis is an ideal reference for any student or researcher interested in drug development for neurodegenerative diseases, autoimmune diseases and MS in particular.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, D ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Inhaltsangabe
Multiple Sclerosis: Epidemiology, Genetics, Symptoms, and Unmet Needs Genetics of Multiple Sclerosis Biomarkers for Multiple Sclerosis Optical Coherence Tomography in Multiple Sclerosis Experimental in vivo Models for Drug Discovery in Multiple Sclerosis Progressive Multiple Sclerosis: Drug Discovery B Cells-based Therapies for Multiple Sclerosis Protein Kinase Inhibitors for the Treatment of Multiple Sclerosis Emerging Drugs and Targets for Remyelination in Multiple Sclerosis Regulation of Oligodendrocyte Differentiation: New Targets for Drug Discovery in Remyelination Cannabinoids as a Therapeutic Approach in Multiple Sclerosis Sigma Receptors as New Target for Multiple Sclerosis Non-Coding RNA and Multiple Sclerosis: New targets for Drug Discovery Diet, Gut Microbiome and Multiple Sclerosis
Multiple Sclerosis: Epidemiology, Genetics, Symptoms, and Unmet Needs Genetics of Multiple Sclerosis Biomarkers for Multiple Sclerosis Optical Coherence Tomography in Multiple Sclerosis Experimental in vivo Models for Drug Discovery in Multiple Sclerosis Progressive Multiple Sclerosis: Drug Discovery B Cells-based Therapies for Multiple Sclerosis Protein Kinase Inhibitors for the Treatment of Multiple Sclerosis Emerging Drugs and Targets for Remyelination in Multiple Sclerosis Regulation of Oligodendrocyte Differentiation: New Targets for Drug Discovery in Remyelination Cannabinoids as a Therapeutic Approach in Multiple Sclerosis Sigma Receptors as New Target for Multiple Sclerosis Non-Coding RNA and Multiple Sclerosis: New targets for Drug Discovery Diet, Gut Microbiome and Multiple Sclerosis
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826